Loss of activity of ceftazidime-avibactam due to MexAB-OprM efflux and overproduction of AmpC cephalosporinase in Pseudomonas aeruginosa isolated from patients suffering from cystic fibrosis

Avibactam is a broad-spectrum inhibitor of β-lactamases approved in combination with ceftazidime for the treatment of Gram-negative infections with limited therapeutic options [1,2]. Since it shows in vitro activity against most class A and class C enzymes [3], including the chromosomally-encoded AmpC cephalosporinase of Pseudomonas aerugin osa (P. aeruginosa) [4], its activity was previously assessed against a large collection (n = 334) of P. aeruginosa isolates from patients suffering from cystic fibrosis (CF).
Source: International Journal of Antimicrobial Agents - Category: Drugs & Pharmacology Authors: Tags: Short communication Source Type: research